Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Receivables (2024 - 2025)

Rani Therapeutics Holdings has reported Receivables over the past 2 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Receivables at $2.0 million for Q4 2025, up 400.0% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (up 400.0% YoY), and the annual figure for FY2025 was $2.0 million, up 400.0%.
  • Receivables for Q4 2025 was $2.0 million at Rani Therapeutics Holdings, up from $600000.0 in the prior quarter.
  • Over the last five years, Receivables for RANI hit a ceiling of $2.0 million in Q4 2025 and a floor of $400000.0 in Q4 2024.